Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Radiological findings help distinguish LAM, PLCH, and BHD to avoid invasive tests.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Removing UBE2N from skin cells causes inflammation and immune response, which can be lessened with specific inhibitors.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Oral itraconazole effectively reaches and treats deep skin layers in guinea pigs.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.

A rare autoimmune disease caused the woman's scalp blisters and hair loss, successfully treated with medication.

SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.

Infliximab successfully treated a severe hair loss case in Sri Lanka.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Dupilumab improves eczema in Netherton Syndrome but not ichthyosis linearis circumflexa.

Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.

Early diagnosis and targeted anti-inflammatory treatments can improve outcomes in androgenetic alopecia with perifollicular inflammation and fibrosis.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.